Georgia is currently home to 1949 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Retrospective Assessment of OviTex PRS (OviTex)
NCT05736848
Recruiting
The objective of this retrospective-prospective, observational study is to evaluate the safety profile overall and within two device types of OviTex PRS in previous pre-pectoral or sub-pectoral implant-based breast reconstructions.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Y Plastic Surgery, Alpharetta, Georgia
Conditions: Reconstructive Surgical Procedures
Register for Updates
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/14/2025
Locations: Augusta University, Augusta, Georgia
Conditions: Ischemic Stroke; Ischemic Attack, Transient
Register for Updates
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05691504
Recruiting
This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a cla... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Advanced Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Register for Updates
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
NCT05586360
Recruiting
This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tumor immune response in men recently diagnosed with localized prostate cancer electing to receive prostatectomy for their care. Half the men will be randomized to receive statins for 8 weeks prior to their surgery, while the other half will receive standard of care.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Prostate Cancer
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004
Recruiting
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Winship Cancer Institute, Atlanta, Georgia
Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC, Colorectal Cancer
Register for Updates
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
NCT05489887
Recruiting
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
08/14/2025
Locations: Augusta University Health, Augusta, Georgia
Conditions: High-risk Neuroblastoma
Register for Updates
A Study of Daratumumab
NCT05438043
Recruiting
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/14/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Multiple Myeloma
Register for Updates
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651
Recruiting
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Grady Health System, Atlanta, Georgia
Conditions: Colorectal Neoplasms
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/14/2025
Locations: Georgia Neurology and Sleep Medicine Assoc, Suwanee, Georgia
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/14/2025
Locations: Local Institution - 0016, Atlanta, Georgia
Conditions: Colitis, Ulcerative
Register for Updates
Spine Procedures Assisted With RoboTics And Navigation
NCT05071144
Recruiting
Creation of a pediatric robotic spine surgery registry will allow for data collection and analysis on the coupled use of robotics and navigation, as well as patient-specific rods in pediatric spine deformity surgery across participating study institutions. Eventually, an educational and informative framework for this technology will be established.
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
08/14/2025
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Spine Deformity, Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis, Spondylolisthesis, Congenital Scoliosis, Neuromuscular Scoliosis
Register for Updates
SELUTION4BTK Trial
NCT05055297
Recruiting
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Cardiovascular Consultants of South Georgia, Thomasville, Georgia
Conditions: Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
Register for Updates